In October we told you about a potential new blockbuster drug for Alzheimer’s from drug giant Eli Lilly. Solanezumab is in the third and final phase of FDA drug trials, and if approved, could bring in at least $7.6 billion in sales by 2024 and probably much more. Other drug companies also have “big” Alzheimer’s drugs in the works. Now the FDA has sent warning letters to five supplement companies targeting the supplement picamilon, which may help with Alzheimer’s, anxiety, and general brain health. The FDA’s attack on picamilon appears to be an attempt to give Big Pharma an unobstructed playing field for their Alzheimer’s drug. Write to the FDA and tell them that picamilon is not a synthetic drug at all, and needs to stay on supplement store shelves!

Read full story...